InnoCare Pharma Limited (SHA:688428)
China · Delayed Price · Currency is CNY 25.34
+0.17 (0.68%)
At close: Nov 14, 2025
InnoCare Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Operating Revenue | 1,425 | 1,008 | 736.99 | 625.4 | 1,043 | 1.36 | Upgrade |
Other Revenue | 1.8 | 1.8 | 1.55 | - | - | - | Upgrade |
| 1,427 | 1,009 | 738.54 | 625.4 | 1,043 | 1.36 | Upgrade | |
Revenue Growth (YoY) | 58.75% | 36.68% | 18.09% | -40.04% | 76368.70% | 9.38% | Upgrade |
Cost of Revenue | 165.59 | 138.44 | 128.44 | 143.4 | 65.67 | - | Upgrade |
Gross Profit | 1,261 | 871.01 | 610.1 | 482.01 | 977.37 | 1.36 | Upgrade |
Selling, General & Admin | 704.34 | 588.49 | 551.01 | 613.27 | 436.89 | 157.58 | Upgrade |
Research & Development | 875.67 | 814.61 | 757.25 | 639.14 | 721.58 | 402.77 | Upgrade |
Other Operating Expenses | 12.06 | 11.13 | -26.76 | 7 | 1.42 | - | Upgrade |
Operating Expenses | 1,593 | 1,416 | 1,282 | 1,259 | 1,160 | 560.35 | Upgrade |
Operating Income | -331.15 | -544.71 | -671.67 | -777.4 | -182.53 | -558.99 | Upgrade |
Interest Expense | -13.24 | -33.79 | -35.21 | -17.05 | -2.64 | -1.14 | Upgrade |
Interest & Investment Income | 73.58 | 178.71 | 197.9 | 145.4 | 135.21 | 98.58 | Upgrade |
Earnings From Equity Investments | - | - | - | -9.71 | -0.6 | - | Upgrade |
Currency Exchange Gain (Loss) | -43.65 | -43.65 | -87.84 | - | 57.14 | 108.29 | Upgrade |
Other Non Operating Income (Expenses) | 45.54 | -0.38 | 6.57 | -244.93 | 17.59 | 30.58 | Upgrade |
EBT Excluding Unusual Items | -268.92 | -443.83 | -590.24 | -903.68 | 24.16 | -322.68 | Upgrade |
Gain (Loss) on Sale of Investments | 4.06 | -30.46 | -53.96 | 6.56 | 6.73 | - | Upgrade |
Asset Writedown | -0.27 | -0.1 | - | - | - | - | Upgrade |
Other Unusual Items | 33.63 | 21.81 | - | 3.4 | -51.01 | -69.18 | Upgrade |
Pretax Income | -231.48 | -452.59 | -644.21 | -893.73 | -20.12 | -391.87 | Upgrade |
Income Tax Expense | 8.01 | 0.26 | 1.43 | - | 46.56 | - | Upgrade |
Earnings From Continuing Operations | -239.49 | -452.86 | -645.63 | -893.73 | -66.68 | -391.87 | Upgrade |
Minority Interest in Earnings | 9.85 | 12.22 | 14.37 | 7.13 | 2.13 | 0.47 | Upgrade |
Net Income | -229.64 | -440.63 | -631.26 | -886.59 | -64.55 | -391.4 | Upgrade |
Net Income to Common | -229.64 | -440.63 | -631.26 | -886.59 | -64.55 | -391.4 | Upgrade |
Shares Outstanding (Basic) | 1,612 | 1,695 | 1,706 | 1,480 | 1,366 | 968 | Upgrade |
Shares Outstanding (Diluted) | 1,612 | 1,695 | 1,706 | 1,480 | 1,366 | 968 | Upgrade |
Shares Change (YoY) | -5.87% | -0.67% | 15.31% | 8.29% | 41.21% | 321.19% | Upgrade |
EPS (Basic) | -0.14 | -0.26 | -0.37 | -0.60 | -0.05 | -0.40 | Upgrade |
EPS (Diluted) | -0.14 | -0.26 | -0.37 | -0.60 | -0.05 | -0.40 | Upgrade |
Free Cash Flow | -162.21 | -443.78 | -920.14 | -792.79 | -2.71 | -423.51 | Upgrade |
Free Cash Flow Per Share | -0.10 | -0.26 | -0.54 | -0.54 | -0.00 | -0.44 | Upgrade |
Gross Margin | 88.40% | 86.28% | 82.61% | 77.07% | 93.70% | 100.00% | Upgrade |
Operating Margin | -23.21% | -53.96% | -90.95% | -124.30% | -17.50% | -40981.38% | Upgrade |
Profit Margin | -16.09% | -43.65% | -85.47% | -141.76% | -6.19% | -28694.65% | Upgrade |
Free Cash Flow Margin | -11.37% | -43.96% | -124.59% | -126.76% | -0.26% | -31049.41% | Upgrade |
EBITDA | -258.76 | -477.69 | -611.8 | -731.46 | -167.2 | -556.92 | Upgrade |
EBITDA Margin | -18.13% | -47.32% | -82.84% | -116.96% | -16.03% | - | Upgrade |
D&A For EBITDA | 72.39 | 67.02 | 59.87 | 45.94 | 15.33 | 2.07 | Upgrade |
EBIT | -331.15 | -544.71 | -671.67 | -777.4 | -182.53 | -558.99 | Upgrade |
EBIT Margin | -23.21% | -53.96% | -90.95% | -124.30% | -17.50% | - | Upgrade |
Revenue as Reported | 1,427 | 1,009 | 738.54 | - | - | - | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.